RxDoctor Payments Data

Saman Sarani, MD

Nephrology · Upland, CANPI 1124333141

Payments from drug & device makers

$4,354in general payments, 2019–2025

Across 178 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$874
  • Amgen$631
  • Vifor Pharma, Inc.$573
  • Akebia Therapeutics Inc$386
  • OPKO Pharmaceuticals, LLC$255
  • Otsuka America Pharmaceutical, Inc.$232
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,21697%
  • Education$1383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,354 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$334,242
Medicare patients
398
Services billed
3,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase13$754,070
VeltassaPatiromer Calcium Sorbitex147$164,207
FarxigaDapagliflozin Propanediol152$113,743
KerendiaFinerenone64$62,269
Sevelamer Hcl24$49,440
LokelmaSodium Zirconium Cyclosilicate33$32,704
VelphoroSucroferric Oxyhydroxide13$30,748
ClinolipidFat Emulsion/Olive/Soy/Phospho52$16,413
ProsolParenteral Amino Acid 20% No.180$11,259
Sevelamer Carbonate32$5,516
Calcium Acetate23$4,541
ClinisolParenteral Amino Acid 15% No.527$3,918
Hydralazine Hcl168$2,668
Comfort Ez Pen NeedlePen Needle, Diabetic11$1,896
Losartan Potassium171$1,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$631$754,07013 claims
AstraZenecaFarxiga, Lokelma$874$146,447185 claims
BayerKerendia$163$62,26964 claims
Fresenius USA Marketing, Inc.Velphoro$74$30,74813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,341 nephrology providers in California.

Other nephrology in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →